SEC Says FDA Chemist Made $3.6M In Insider Trading

Law360, New York (March 29, 2011, 7:32 PM EDT) -- The U.S. Securities and Exchange Commission accused a Food and Drug Administration chemist in Maryland federal court on Tuesday of using internal information about upcoming drug approval decisions to make trades worth more than $3.6 million.

The SEC said in a U.S. District Court for the District of Maryland complaint that Cheng Yi Liang, who works at the FDA's Center for Drug Evaluation and Research, regularly looked up information about a drug's pending application and then traded in the drug company's securities prior to any public...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.